Matt Webber is an experienced personal finance writer, researcher, and editor. He has published widely on personal finance, marketing, and the impact of technology on contemporary arts and culture.

With close to a decade of writing and editing experience, Maisha specializes in service journalism and has produced work in the lifestyle, financial services, real estate, and culture spaces. She uses ...

The Food and Drug Administration on Thursday proposed excluding Novo Nordisk and Eli Lilly’s ‌weight-loss drugs from a key compounding list, potentially limiting large-scale production by outsourcing ...

A recent op-ed in the Washington Post describes the story of an author who decided he wanted to lose weight. Although he was healthy, he heard from friends how easy and effective GLP-1 medications ...

Learn about compound interest. We will look at how to determine the final value, initial value, interest rate and years needed. We will investigate problems compounded continuously, daily, weekly, ...

The compound annual growth rate, or CAGR, of an investment or other unit of value is the average annual amount it grows over a period of years assuming profits are reinvested during the period. In ...

Drugmaker Eli Lilly says some copycat versions of its GLP-1 medications pose unique safety concerns — here’s what you need to know. A new study funded by Eli Lilly found that mixing compounded ...

WASHINGTON, March 12 (Reuters) - Compounded weight-loss drugs that contain vitamin B12 and the ‌main ingredient in Eli Lilly's (LLY.N), opens new tab Zepbound could present health risks to consumers ...

Semaglutide treats type 2 diabetes and can support weight loss with diet and exercise. It works by mimicking glucagon-like peptide-1 (GLP-1) to boost insulin and reduce appetite. Compounded ...

The FDA is taking no prisoners as it continues its efforts to combat widespread GLP-1 drug compounding. In its latest offensive, the agency has unleashed a fresh set of 30 warning letters targeting ...

The Food and Drug Administration (FDA) on Tuesday sent 30 telehealth companies warning letters about their “illegal” sales of compounded GLP-1s, building off increasing pressure to tamp down on the ...